Abstract
Cancer immunotherapy has fundamentally reshaped oncology by harnessing the immune system to eliminate malignant cells. Immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 have achieved durable remissions in select cancers, yet most patients exhibit resistance due to tumor heterogeneity, immunometabolic rewiring, and the immunosuppressive tumor microenvironment. To address these limitations, next-generation immunotherapies have emerged, targeting multiple layers of immune regulation. These include co-inhibitory and co-stimulatory checkpoint modulators, bispecific antibodies, adoptive cell therapies, cancer vaccines, oncolytic viruses, cytokine-based strategies, and synthetic immunomodulators that activate innate sensors. Nanotechnology and in vivo immune engineering further enhance specificity, reduce toxicity, and broaden applicability. Combination immunotherapy has become central to overcoming resistance, with rational regimens integrating ICIs, cytokines, vaccines, and targeted agents. Biomarker-guided strategies, leveraging tumor mutational burden, immune cell infiltration, and multi-omic profiling, are enabling personalized approaches. However, immune-related adverse events and variability in therapeutic responses necessitate predictive biomarkers and improved patient stratification. Emerging frontiers include microbiome-targeted interventions, chronotherapy, and AI-driven modeling of tumor–immune dynamics. Equally critical is ensuring global equity through inclusive trial design, diverse biomarker validation, and expanded access to cutting-edge therapies. This review provides a comprehensive analysis of multimodal immunotherapeutic strategies, their mechanistic basis, and clinical integration. By unifying innovation in immunology, synthetic biology, and systems medicine, next-generation cancer immunotherapy is poised to transition from a transformative intervention to a curative paradigm across malignancies.
Introduction
Cancer immunotherapy has transformed the therapeutic landscape of oncology by harnessing the immune system to detect and eliminate malignant cells1. Immune checkpoint inhibitors (ICIs), particularly those targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1), have achieved durable clinical responses across multiple malignancies, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) (Nagasaki et al., 2022; Sun et al., 2023; Pardoll, 2012). However, despite these advances, a substantial proportion of patients do not respond or eventually relapse. Mechanisms of resistance include intratumoral heterogeneity, immunometabolic rewiring such as the Warburg effect, and the immunosuppressive architecture of the tumor microenvironment (TME) (Schoenfeld and Hellmann, 2020; Usset et al., 2024; ; Ribas and Wolchok, 2018).
These limitations have catalyzed efforts to expand the immunotherapeutic arsenal beyond classical ICIs, leading to the development of novel modalities that engage diverse components of the immune system. These include cancer vaccines that deliver tumor-specific antigens to dendritic cells (DCs), oncolytic viruses (OVs) that promote direct tumor lysis and immune activation (Shalhout et al., 2023), bispecific antibodies (BsAbs) that redirect T cells to tumor cells (Trabolsi et al., 2024; ), adoptive cell therapies (ACTs), such as chimeric antigen receptor (CAR) and T cell receptor (TCR)-engineered cells, confer engineered cytotoxicity (Peng et al., 2024; ), and cytokine-based interventions (). Collectively, these approaches target multiple layers of immunological control, from enhancing antigen presentation and T cell priming to reprogramming the TME, to achieve robust and durable antitumor immunity (; ; ). Additionally, synthetic immunomodulators, such as engineered cationic helical polypeptides that activate innate immune sensors (), and microbiome-based interventions that reshape systemic and local immunity (Zheng et al., 2020), are expanding the therapeutic landscape. Nanotechnology-driven delivery systems further enable precise antigen targeting, reduce systemic toxicity, and support in vivo immune cell engineering.
Combination immunotherapy has emerged as a cornerstone of modern clinical development (). Rationally designed regimens, such as dual ICI blockade (anti–PD-1 plus anti–CTLA-4), checkpoint inhibition combined with co-stimulatory agonists (GITR, OX40, CD40), and combinations with radiotherapy, chemotherapy, or targeted agents, are actively being explored to address immune escape and resistance (Zhang et al., 2025; ; ). Increasingly, biomarker-guided selection and molecular profiling are guiding the deployment of these combinations, enabling personalized and context-specific strategies. This review provides a comprehensive analysis of emerging immunotherapeutic strategies and their mechanistic underpinnings, clinical advances, and potential for integration into rational combination regimens. Particular emphasis is placed on how these multimodal interventions converge to rewire cancer immunity, overcome therapeutic resistance, and extend the promise of durable clinical benefit across diverse tumor types.
Cancer vaccines
Preventive cancer vaccines
Preventive vaccines are designed to reduce the risk of cancer by targeting oncogenic viral infections (). Currently, two vaccines are approved for cancer prevention: the human papillomavirus (HPV) vaccine and the hepatitis B virus (HBV) vaccine. Prophylactic HPV vaccines, available in bivalent and quadrivalent formulations, have demonstrated over 90% efficacy in preventing cervical cancer and other HPV-related malignancies (). These vaccines also confer indirect protection to men through herd immunity (). Similarly, HBV vaccination is a cornerstone of public health strategies to prevent HBV-induced HCC. Integration into national immunization programs has significantly decreased HBV incidence and reduced acute infections, particularly among children and adolescents (). Vaccination at birth prevents chronic HBV infection in over 90% of cases. However, challenges persist in preventing vertical transmission, especially from hepatitis B e-antigen (HBeAg)-positive mothers (). Advances such as Heplisav-B offer improved immunogenicity and safety over older vaccines like Engerix-B, providing enhanced protection for non-responders (Splawn et al., 2018). In addition, efforts are underway to develop therapeutic vaccines targeting chronic HBV by enhancing immune clearance where prophylactic vaccination is insufficient ().
Therapeutic cancer vaccines
Therapeutic vaccines are designed to induce an immune response against established tumors. These vaccines deliver tumor-specific or tumor-associated antigens (TAAs), to APCs, particularly DCs, which in turn activate CTLs to recognize and kill cancer cells (Saxena et al., 2021). The goals of therapeutic vaccines include halting tumor progression, eradicating residual disease, and preventing relapse. Technological advancements in whole-exome/genome sequencing and bioinformatics have enabled the identification of neoantigens—tumor-specific mutated proteins with high immunogenicity and low tolerance, enabling personalized vaccine design (). In addition to neoantigens, shared TAAs expressed across multiple tumor types are commonly targeted (Saxena et al., 2021). Therapeutic vaccines function by enhancing antigen presentation, stimulating DC maturation, and promoting durable T cell–mediated immune responses within the TME, where both innate (natural killer (NK) cells, macrophages, neutrophils) and adaptive (T and B cells) immune cells coordinate antitumor immunity ().
To achieve these goals, various vaccine platforms have been developed. DNA, RNA, and peptide-based vaccines deliver tumor antigens in forms that are processed and presented by APCs, inducing CTL responses (). Nanoparticle-based systems further enhance vaccine efficacy by stabilizing antigens, improving cellular uptake, and directing delivery to specific immune cell subsets (). Ex vivo–loaded DC vaccines involve isolating DCs from the patient, pulsing them with tumor antigens in vitro, and reinfusing them to generate a robust and targeted immune response (). Irradiated tumor cell vaccines use tumor cells that have been rendered non-replicative yet maintain antigenicity, often engineered to secrete immune-activating factors that boost T cell priming (). A notable example is Sipuleucel-T, approved in 2010 for metastatic castration-resistant prostate cancer. This autologous DC-based vaccine loads patient-derived DCs with a prostate antigen (PAP-GM-CSF fusion protein) and reinfuses them to stimulate a targeted immune response () (Figure 1A).
FIGURE 1
Beyond conventional vaccines, innovative immunotherapeutic strategies continue to emerge. One of the most established is intravesical Bacillus Calmette–Guérin (BCG) therapy for early-stage non-muscle invasive bladder cancer (NMIBC). BCG elicits a strong, localized immune response that helps prevent tumor recurrence. For patients who fail BCG therapy, the FDA-approved gene therapy nadofaragene firadenovec (Adstiladrin) provides a new option. This therapy uses a replication-deficient adenoviral vector to deliver human interferon alfa-2b cDNA directly to the bladder, showing high complete response rates in Phase III trials (; Narayan et al., 2024).
Ongoing clinical trials continue to expand the therapeutic landscape. At Memorial Sloan Kettering Cancer Center, an mRNA-based vaccine targeting pancreatic cancer has shown promise in Phase I trials. This personalized vaccine induced robust CD8+ T cell responses that persisted for up to 4 years and correlated with reduced relapse at a 3-year follow-up (Sethna et al., 2025). Overall, vaccine development for cancer treatment is one of the most developing fields currently. Future investigations and ongoing clinical trials will further delineate the optimal targets of the immune response, dosage and vaccine platforms, including their integration into combination therapies aimed at maximizing patient outcomes in the face of a heterogeneous disease landscape.
Bi-specific T cell engagers and dual-affinity retargeting antibodies
In recent decades, BsAbs have emerged as a promising therapeutic strategy for hematologic malignancies (Tian et al., 2021) and are increasingly being explored for the treatment of solid tumors, including lung, breast, pancreatic, and prostate cancers (Palecki et al., 2024; Simão et al., 2023). Among the more than 100 bispecific formats developed, bi-specific T cell engagers (BiTEs) stand out due to their design and ongoing structural innovations (). BiTEs are recombinant proteins composed of two antigen-binding modules connected by a short linker or a shared Fc domain. One module binds a TAA on cancer cells, while the other engages the CD3-TCR complex on T cells. This dual binding facilitates the selective recruitment and activation of T cells against tumor cells, leading to enhanced cytotoxic responses and effectively harnessing the body’s immune system to combat cancer. The modulation of BiTEs allows them to be engineered against virtually any cell surface TTA, providing a versatile platform for the treatment of diverse cancer types (Simão et al., 2023). As of 2025, at least nine FDA-approved BiTEs have been approved, including BiTEs and BiTE-like constructs. Blinatumomab, targeting CD19 on B cells, is approved for the treatment of relapsed or refractory (r/r) B cell precursor acute lymphoblastic leukemia (BCP-ALL) and BCP-ALL with minimal residual disease (; Sun et al., 2015). Teclistamab, a bispecific mAb targeting B cell maturation antigen (BCMA), is indicated for r/r multiple myeloma (). Similarly, Talquetamab targets GPRC5D on myeloma cells and has been approved for r/r multiple myeloma (). Elranatamab, another BCMA-targeting BiTE, is approved for heavily pretreated r/r multiple myeloma (). Tebentafusp, distinct from conventional BiTEs, utilizes a soluble high-affinity TCR to target a gp100-derived peptide presented by MHC class I complexes and is approved for uveal melanoma (). Epcoritamab, which engages both CD20 on B cells and CD3 on T cells, is approved for r/r diffuse large B cell lymphoma (DLBCL) (). Tarlatamab, targeting delta-like ligand 3 (DLL3), has been approved for SCLC in patients who have progressed after platinum-based chemotherapy (). Glofitamab, a 2:1 CD20 × CD3 BiTE, is FDA-approved for relapsed/refractory DLBCL after ≥2 prior therapies. Its unique bivalent CD20 binding enhances tumor targeting and T cell activation, with obinutuzumab pre-treatment reducing CRS (). Mosunetuzumab, another CD20 × CD3 BiTE, is approved for relapsed/refractory follicular lymphoma. It uses a step-up dosing regimen to mitigate CRS and has shown high complete response rates in heavily pretreated patients (Sehn et al., 2025).
Despite the success of BiTEs in hematologic malignancies, their efficacy in solid tumors remains limited due to barriers such as poor T cell infiltration and the presence of an immunosuppressive TME. To address these challenges, innovative strategies are being developed, including checkpoint inhibitory T cell engagers (CiTEs) (Szijj et al., 2023), simultaneous multiple interaction T cell engagers (SMiTEs) (), and oncolytic virus-mediated BiTE delivery systems. These novel approaches aim to enhance T cell activation, overcome immune suppression, and improve therapeutic outcomes in solid tumors (). Additionally, combining BiTEs with other modalities, such as CAR-T cell therapy and ICIs, is being actively explored to further boost anti-tumor responses (Yin et al., 2022). Ongoing clinical studies and trials are essential for refining these therapies, extending patient remission, and minimizing relapse rates (Figure 1B). The expanding repertoire of BsAbs reflects ongoing advances in molecular engineering. Dual-affinity retargeting antibodies (DARTs) have been developed to improve stability and target engagement compared to earlier bispecific designs (). Furthermore, innovations in the engineering of single-chain variable fragments (scFvs), which serve as modular building blocks for bispecific formats, have enabled the simultaneous targeting of multiple tumor antigens (). This strategy is particularly valuable for addressing tumor heterogeneity, a major factor complicating treatment resistance. While the challenges associated with toxicity and solid tumor targeting persist, the precision and adaptability of BiTEs position them as a powerful modality in the evolving landscape of cancer immunotherapy.
Adoptive cell therapies
ACTs represent a transformative modality in cancer immunotherapy, involving the isolation, expansion, and reinfusion of autologous or allogeneic immune cells to enhance tumor eradication. Among ACT approaches, TILs and genetically engineered T cells are widely employed. The latter includes T cells modified to express transgenic TCRs or CARs. Unlike TILs and TCR-modified T cells, CAR T cells operate independently of MHC-mediated antigen presentation, enabling broader and more versatile targeting of TAAs, a property that has made them a cornerstone in adoptive immunotherapy strategies () (Figure 1C). CAR T cells have demonstrated remarkable clinical success in hematologic malignancies. To date, six CAR T therapies have received FDA approval: four targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel) and two targeting BCMA (idecabtagene vicleucel and ciltacabtagene autoleucel) for multiple myeloma (). These therapies show high response rates in B-cell precursor ALL, large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL), and relapsed/refractory multiple myeloma (RMM) (Zugasti et al., 2025; ). Clinical trials have also expanded to target CD22, showing promise in ALL, and further preclinical efforts include dual-targeting strategies to mitigate antigen loss and tumor escape (; ).
Structurally, CARs comprise an scFv domain for antigen recognition, a hinge region, a transmembrane domain, and intracellular signaling domains such as CD3ζ and co-stimulatory elements (e.g., CD28 or 4-1BB), which define their generation and impact persistence and function (Safarzadeh Kozani et al., 2022). Second-generation CARs have become the clinical standard, offering enhanced cytotoxicity and memory formation (). New designs now incorporate logic gating, cytokine expression, and safety switches to enhance control and efficacy. Despite success in blood cancers, CAR T cell efficacy in solid tumors remains limited due to several challenges: scarcity of tumor-specific antigens, risk of on-target off-tumor toxicity, antigen heterogeneity, and an immunosuppressive TME that impairs T cell trafficking and function. To overcome these barriers, innovative in vivo engineering strategies have emerged, aiming to simplify manufacturing and broaden applicability. One major innovation is in vivo CAR T cell generation, which bypasses ex vivo cell manipulation and instead employs targeted delivery systems, such as lipid nanoparticles (LNPs), polymeric nanoparticles, viral vectors (e.g., lentivirus, AAV), and bioinstructive scaffolds, to directly engineer immune cells within the body (; ). Among these, LNP–mRNA systems have shown particular promise due to their transient expression profiles, lower immunogenicity, and scalable manufacturing, benefiting from platforms used in mRNA vaccines (; ). For instance, maleimide-functionalized LNPs conjugated to CD3-targeting antibodies have successfully delivered CD19 CAR mRNA to splenic T cells in preclinical models, achieving effective B cell depletion with minimal liver toxicity. In addition, Cas9-packaging enveloped delivery vehicles (Cas9-EDVs) allow for simultaneous in vivo CAR insertion and gene editing (e.g., TRAC knockout), facilitating allogeneic cell generation while reducing graft-versus-host risks. Virus-mimetic fusogenic nanovesicles (FuNVs) present an alternative by directly inserting preformed CAR proteins into T cells, enabling transient functionality without gene integration (; ).
However, the use of CAR T cells is not without risk. The two most significant adverse effects are CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) (). CRS results from excessive cytokine secretion following T cell activation, presenting with fever, hypotension, and potentially multiorgan dysfunction. ICANS often co-occurs with severe CRS and is characterized by neurologic symptoms such as confusion, seizures, and cerebral edema, likely due to cytokine-induced blood-brain barrier disruption (Santomasso et al., 2023).
As adoptive therapies expand, alternative effector cells like NK cells and macrophages are increasingly being explored for CAR engineering. These innate immune cells offer unique biological properties that may help overcome the limitations faced by CAR T cell therapies, particularly in solid tumors. A leading example of CAR NK development is FT596, the first-in-class, off-the-shelf, induced pluripotent stem-cell (iPSC)-derived CAR NK product. FT596 is genetically engineered to express a CD19-specific CAR, an IL-15 receptor fusion to enhance persistence, and a high-affinity CD16 Fc receptor to facilitate antibody-dependent cellular cytotoxicity (ADCC) (; ; Rezvani, 2019). In a Phase I trial involving patients with relapsed or refractory B cell malignancies, FT596 demonstrated a favorable safety profile, including an absence of cytokine release syndrome (CRS), and encouraging antitumor activity, underscoring its potential as an allogeneic and low-toxicity platform ().
Parallel efforts have led to the development of CT-0508, a first-in-class autologous CAR macrophage therapy designed to target HER2-expressing solid tumors. This therapy not only mediates direct cytotoxicity through phagocytosis but also remodels the TME by enhancing antigen presentation and promoting T cell infiltration (; Morva et al., 2025). Early-phase clinical evaluation of CT-0508 has demonstrated feasibility, biological activity, and favorable tolerability in patients with advanced HER2-positive cancers (Reiss et al., 2022; Reiss et al., 2025). Complementing these clinical approaches, preclinical models of in vivo CAR macrophage engineering, using mannose-targeted LPNs or biodegradable polymeric carriers, have shown promising efficacy in difficult-to-treat tumors such as pancreatic and HCC (). These examples underscore the growing interest in using innate immune cells to overcome the limitations of CAR T therapy in solid tumors and expand the adoptive cell therapy toolkit.
Cytokine therapy
Cytokines are small, soluble proteins that mediate cell-to-cell communication and regulate the activation, differentiation, and function of both innate and adaptive immune responses. These key regulators of immune responses have been explored as cancer therapeutics due to their ability to activate and expand immune effector cells (). Interleukin-2 (IL-2) and interferon-alpha (IFN-α) were among the first cytokines used in oncology, showing clinical benefit in subsets of patients with metastatic melanoma and RCC by enhancing cytotoxic immune activity. However, their clinical use has been hindered by systemic toxicity, including vascular leak syndrome, neuropsychiatric effects, and multiorgan dysfunction, largely due to their pleiotropic nature (Saxton et al., 2023). To improve safety and efficacy, efforts have focused on engineering cytokines with extended half-lives (e.g., pegylation), tumor-targeted delivery systems, and combinations with other immunotherapies (). Notably, combining cytokines with ICIs or mAbs is being investigated to boost antitumor immunity while minimizing adverse effects (). Advances in cytokine engineering and biomarker-driven approaches are expected to refine patient selection and therapeutic outcomes. To address the limitations of pleiotropy and systemic toxicity, cytokine mimetics have emerged as a promising strategy. Using computational design, de novo mimetics such as Neo-2/15, engineered by David Baker’s lab, selectively engage IL-2 receptor βγ chains, avoiding CD25-mediated toxicities while enhancing effector T cell activity and antitumor efficacy (Silva et al., 2019). These mimetics offer improved pharmacokinetics, reduced off-target inflammation, and greater tumor selectivity. To enhance tumor targeting and minimize systemic exposure, a variety of delivery technologies are under development. Nanoparticle-based carriers, hydrogels, and immunocytokine conjugates offer controlled release, preferential tumor accumulation, and improved pharmacokinetics. For instance, LNP-encapsulated cytokine mRNAs (e.g., IL-7 + IL-21) delivered intratumorally induced strong CD8+ T cell responses and durable antitumor immunity in preclinical settings (). Reviews highlight how nanocarriers enhance efficacy of cytokines via localized delivery while minimizing systemic toxicity (Wang et al., 2025).
Oncolytic viruses
OVs represent a novel class of cancer therapeutics capable of selectively infecting and lysing tumor cells while sparing normal tissues (; Rivera-Orellana et al., 2025) (Figure 1D). Their antitumor activity is mediated through direct oncolysis and the induction of systemic immune responses (). Upon infection, OVs induce cellular stress pathways and stimulate the release of type I interferons (IFNs), activating DCs, cytotoxic CD8+ T lymphocytes, and NK cells (). Tumor lysis releases PAMPs and DAMPs, TAAs, and neoantigens, promoting both innate and adaptive immune activation (Sun et al., 2023). Among OVs, talimogene laherparepvec (T-VEC), a modified herpes simplex virus type 1 (HSV-1) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), is the most clinically advanced and FDA-approved for metastatic melanoma (). Clinical results from the OPTiM Phase III trial demonstrated improved overall and durable response rates compared to conventional therapies (). Other platforms under investigation include HSV-based vectors (e.g., HF10, HSV1716) (Reddy et al., 2024), adenoviruses (e.g., Oncorine, ONYX-015, CG0070) (; ), reovirus (e.g., Reolysin, targeting Ras-mutated tumors) (Norman and Lee, 2000), and vaccinia virus (e.g., JX-594, also expressing GM-CSF) (; ). These agents exploit tumor-specific vulnerabilities to enhance selectivity and immune engagement. OVs are increasingly evaluated in combination with ICIs, chemotherapy, and radiotherapy to amplify efficacy and overcome immune resistance. Ongoing developments focus on novel viral platforms, such as measles virus, Newcastle disease virus, and Zika virus, and biomarker-guided strategies to personalize therapy and expand clinical utility across diverse cancer types (Zhang and Rabkin, 2021).
Synthetic cationic helical polypeptides
Synthetic cationic helical polypeptides have emerged as a novel class of immunotherapeutic agents capable of inducing potent antitumor immune responses, particularly through the activation of APCs. These engineered polypeptides represent a promising strategy for the treatment of advanced and metastatic breast cancer by engaging critical innate immune pathways (). Upon exposure, they activate key intracellular sensors including TLR9, cyclic GMP-AMP synthase (cGAS), and the stimulator of interferon genes (STING) adaptor protein. This activation cascade leads to the production of IFNs, which in turn stimulate robust cytotoxic T cell responses directed against tumor cells (Vormehr et al., 2019). The therapeutic efficacy of these polypeptides is rooted in their precisely designed physicochemical properties—electrostatic charge, hydrophobicity, and helical secondary structure. These features enhance systemic activity, immunogenicity, and serum stability (). Mechanistically, synthetic polypeptides induce endoplasmic reticulum (ER) stress in APCs, prompting the release of mitochondrial DNA (mtDNA) into the cytosol. This mtDNA acts as a danger signal that activates innate immune pathways, thereby augmenting inflammatory responses, enhancing antigen presentation, and promoting phagocytosis of tumor cells by APCs (). Among the different polypeptides investigated, protamine alpha (PTMA), P1, and PS exhibited distinct characteristics in terms of serum stability, hydrophilicity, and pro-inflammatory gene induction. The P1 polypeptide emerged as the most promising candidate due to its optimized helical conformation, achieved through the incorporation of ethylene glycol moieties. This structural refinement endowed P1 with superior serum stability, prolonged circulation time, and enhanced tumor accumulation (). In preclinical models, P1 effectively suppressed tumor growth and promoted the infiltration of IFNγ-producing T cells into the TME. It also improved APC-mediated phagocytosis and supported memory T cell development, critical for achieving durable antitumor immunity. Combination therapy using P1 and anti-PD-1 checkpoint blockade further enhanced antitumor efficacy. This combinatorial approach synergistically activated both TLR9-MyD88 and c-GAS-STING pathways, leading to the phosphorylation and nuclear translocation of interferon regulatory factor 3 (p-IRF3), a central transcription factor for IFN production. In murine models of 4T1 breast cancer brain metastases, this strategy significantly reduced tumor burden and prolonged survival, with 25% of treated mice surviving up to 150 days without evidence of tumor recurrence (). From a clinical perspective, synthetic cationic helical polypeptides offer multiple advantages, including synthetic tunability, selectivity for immune activation without inducing global inflammation, scalable production, and the potential for systemic administration with limited off-target effects (Zheng et al., 2025). However, some limitations remain, such as limited pharmacokinetic and toxicity data in humans, the need for improved tissue targeting in complex tumor environments, and uncertainty regarding long-term immune consequences of sustained innate activation (Svenson et al., 2022). Further optimization of their structure, formulation, and delivery platforms will be critical for successful translation into clinical practice (Weiss et al., 2022). The rational design of synthetic cationic helical polypeptides represents a transformative direction in cancer immunotherapy, particularly for solid tumors. P1’s ability to trigger intracellular DNA sensors via ER stress-induced mtDNA release exemplifies its multifunctional immunostimulatory capacity. By integrating molecular engineering with immunologic insights, these polypeptides offer a versatile and effective platform for inducing systemic and durable antitumor responses.
Current landscape of combination therapy strategies
Combination immunotherapy has become essential for overcoming resistance mechanisms that limit the durability of ICI monotherapies. Guided by biomarkers and tumor profiling, current strategies aim to enhance efficacy by simultaneously targeting immune suppression, tumor-intrinsic pathways, and the TME (; Sharma et al., 2023) (Table 1).
TABLE 1
| Combination category | Representative examples | Strengths/mechanistic rationale |
|---|---|---|
| ICI + chemotherapy | Nivolumab + platinum doublet chemo (NSCLC, CheckMate 9LA) | Enhances antigen release and T cell priming; converts cold tumors into inflamed tumors |
| ICI + targeted therapy | Atezolizumab + bevacizumab (HCC, IMbrave150) | Normalizes vasculature and improves T cell infiltration; overcomes resistance to monotherapy |
| ICI + radiation | Durvalumab + chemoradiation (NSCLC, PACIFIC trial) | Induces immunogenic cell death; enhances antigen presentation and T cell recruitment |
| ICI + cancer vaccines | mRNA-4157/V940 + pembrolizumab (KEYNOTE-942) | Boosts T cell priming and broadens TAA recognition; enhances immune memory |
| ICI + oncolytic viruses | T-VEC + ipilimumab (melanoma, NCT01740297) | Enhances local inflammation and T cell trafficking; synergistic antitumor activity |
| ICI + microbiome modulation | FMT + anti-PD-1 in melanoma | Restores immune tone and ICI sensitivity; improves patient stratification |
| CAR T + checkpoint blockade | CAR T cells + PD-1 blockade (preclinical and early trials) | Overcomes CAR T exhaustion and immunosuppression in TME |
| CAR T + cytokines or small molecules | IL-15 superagonists + CAR T (e.g., N-803, preclinical) | Improves CAR T persistence, expansion, and cytotoxicity |
Combination immunotherapy strategies.
Combination strategies with immune checkpoint inhibitors
The development of combination immunotherapy has become essential to overcoming the resistance mechanisms that limit the efficacy of ICIs as monotherapies. Dual checkpoint blockade, such as the combination of ipilimumab (CTLA-4 inhibitor) and nivolumab (PD-1 inhibitor), has demonstrated superior efficacy and received FDA approval for multiple cancers, including melanoma, NSCLC, RCC, HCC, and microsatellite instability-high (MSI-high) colorectal cancer (; Olson et al., 2021; Wolchok et al., 2022; ). The approval of nivolumab with the LAG-3 inhibitor relatlimab for advanced melanoma underscores the expanding therapeutic potential of targeting additional inhibitory receptors (Tawbi et al., 2022; ). Combinations under clinical evaluation include PD-L1 inhibitors (atezolizumab and dostarlimab) with TIGIT (tiragolumab) or TIM-3 (cobolimab) antagonists, as well as bispecific antibodies (LY3415244) that engage multiple checkpoints (; Rousseau et al., 2023; ; Zhang et al., 2025; ; Sauer et al., 2023; ). Beyond inhibitory checkpoints, costimulatory agents offer another promising avenue. These agents enhance T cell activation and effector function, especially when used alongside inhibitory ICIs. For instance, pembrolizumab (anti–PD-1) is being evaluated in combination with INBRX-106, an OX40 agonist, for advanced solid tumors (Postel-Vinay et al., 2023). Similarly, combinations of PD-1 inhibitors like pembrolizumab or spartalizumab with TRX518, a GITR agonist, are being tested in solid tumors and lymphomas (). Cytokines are also being integrated into combination regimens to enhance immune activation. IL-12 and IFNs can promote a proinflammatory TME by enhancing DC activation and antigen presentation, while IL-2 supports T cell proliferation and survival. Ongoing studies are evaluating ICIs in combination with IL-12, IL-2, or IFNγ across indications such as melanoma, solid tumors, and lymphomas (Zibelman et al., 2023; ).
Integration with conventional and targeted therapies
ICIs are increasingly combined with conventional therapies to enhance immune priming and tumor clearance. Chemotherapy induces immunogenic cell death and facilitates antigen release, augmenting the effectiveness of checkpoint blockade. Clinical trials have evaluated combinations such as nivolumab with gemcitabine and cisplatin in esophageal squamous cell carcinoma, NSCLC, and advanced cervical cancer (; ; van der Heijden et al., 2023), as well as atezolizumab with carboplatin and etoposide for SCLC (; ). Radiotherapy promotes a proinflammatory microenvironment and antigen exposure, with several trials exploring its synergy with ICIs in solid tumors. For instance, durvalumab (anti–PD-L1) and tremelimumab (anti–CTLA-4) have been tested in combination with hypofractionated radiotherapy for NSCLC (; Schoenfeld et al., 2022; ), while stereotactic radiotherapy combined with nivolumab and ipilimumab has shown efficacy in Merkel cell carcinoma (). Neoadjuvant and adjuvant strategies that incorporate ICIs are being evaluated in early-stage clinical trials to improve long-term immune surveillance and prevent recurrence. Trials include neoadjuvant regimens such as dostarlimab for dMMR colorectal cancer, nivolumab plus ipilimumab for melanoma, atezolizumab for HER2-positive breast cancer, and pembrolizumab for early-stage NSCLC (; ; Wakelee et al., 2023; ). Adjuvant applications of pembrolizumab and atezolizumab are being studied for NSCLC and RCC (; ). In parallel, ICIs are being integrated with targeted therapies, including tyrosine kinase inhibitors (TKIs) and anti-angiogenic agents, which normalize the tumor vasculature and enhance T cell infiltration. Pembrolizumab combined with lenvatinib or axitinib has shown success in RCC and endometrial carcinoma (; ; Rini et al., 2019), while nivolumab with cabozantinib is approved for advanced RCC (). Additionally, anti-VEGF therapy combined with ICIs, such as atezolizumab plus bevacizumab, enhances T cell activation and is FDA-approved for HCC (). Targeting oncogenic drivers in melanoma, the combination of atezolizumab with cobimetinib (anti-MEK) and vemurafenib (anti-BRAF) has been approved for BRAF-V600E-mutant melanoma ().
Emerging and innovative combinations
Innovative approaches are rapidly expanding the therapeutic scope of immunotherapy. One major area of progress involves personalized neoantigen vaccines, which aim to elicit tumor-specific T cell responses. These vaccines are being evaluated in combination with ICIs, such as ipilimumab or nivolumab, in melanoma, NSCLC, urothelial carcinoma, and glioblastoma multiforme (Ott et al., 2017; Ott et al., 2020; ). Similarly, bispecific T cell engagers (e.g., blinatumomab and PSMA-targeting BiTEs) are designed to redirect T cells toward tumor cells and are under investigation in both solid and hematologic malignancies (; ). Another promising avenue involves the integration of adoptive cell therapy with ICIs. CAR T cell therapies co-administered with PD-1 or PD-L1 inhibitors are being explored to overcome T cell exhaustion and the immunosuppressive TME (Zhao et al., 2015; ). In parallel, IL-15 superagonists such as N-803 have shown the potential to enhance CAR T cell persistence and antitumor efficacy in both preclinical and early-phase clinical studies (Romee et al., 2018; ). Radiotherapy is also being combined with ICIs to potentiate immune responses by promoting antigen exposure and proinflammatory signaling. Hypofractionated and stereotactic radiotherapy regimens have been tested with durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor) in NSCLC (Pakkala et al., 2020; Twyman-Saint Victor et al., 2015; Zhang et al., 2022), and in combination with nivolumab and ipilimumab in Merkel cell carcinoma (). These approaches aim to convert immunologically “cold” tumors into “hot” ones that are more susceptible to immune attack. OVs, such as T-VEC, have also demonstrated synergy with ICIs by inducing immunogenic cell death and amplifying systemic immune activation, particularly in melanoma (; ). In parallel, metabolic modulators are being developed to counteract immunosuppressive metabolites like lactate within the tumor microenvironment, thereby restoring T cell function (Zheng et al., 2024). Another Frontier in combination immunotherapy involves modulation of the gut microbiota. Probiotics, prebiotics, and dietary interventions are being tested as adjuncts to ICIs to enhance systemic immune tone and therapeutic response (). Finally, novel multi-checkpoint blockade strategies are emerging. A recent neoadjuvant regimen involving simultaneous inhibition of PD-1, CTLA-4, and LAG-3 demonstrated durable tumor control in glioblastoma, with no recurrence at 17 months. This promising result has prompted the launch of a dedicated clinical trial (GIANT, NCT06816927) to further investigate this triple-combination approach (Long et al., 2025). Together, these innovative combination strategies exemplify the future of precision immuno-oncology, offering the potential to overcome therapeutic resistance, enhance efficacy, and deliver durable benefit across a wide range of tumor types.
Conclusion and future perspectives
Cancer immunotherapy has revolutionized oncology by mobilizing the immune system to target malignant cells, most notably through ICIs. Despite durable responses in select malignancies, many patients experience primary or acquired resistance due to tumor heterogeneity, immunometabolic rewiring, and the immunosuppressive TME (Wang et al., 2022). These limitations have catalyzed the development of next-generation immunotherapies, including novel inhibitory and co-stimulatory checkpoints, bispecific antibodies (), adoptive cell therapies (), cancer vaccines (Zaidi et al., 2025), cytokine-based interventions (), synthetic immunomodulators (), and microbiome-targeted strategies (Sun et al., 2025), each aiming to reprogram antitumor immunity and expand therapeutic efficacy across both solid and hematologic malignancies (Table 2).
TABLE 2
| Modality | Mechanism of action | Clinical applications | Representative FDA approvals/landmark trials | Strengths and limitations |
|---|---|---|---|---|
| Immune checkpoint inhibitors | Block CTLA-4 and PD-1/PD-L1 to restore T cell function | Melanoma, NSCLC, RCC, MSI-H CRC | Ipilimumab (CTLA-4) in melanoma (FDA 2011); Nivolumab + ipilimumab in NSCLC (CheckMate 227) | Durable responses in some tumors; limited efficacy in “cold” tumors; risk of irAEs |
| Cancer vaccines | Stimulate immune response via tumor-specific antigens delivered by DNA/RNA/peptide or DC-based platforms | HPV/HBV prevention, prostate cancer (Sipuleucel-T), pancreatic cancer (mRNA vaccine) | HPV (Gardasil), HBV (Heplisav-B), Sipuleucel-T (FDA 2010); Moderna mRNA-4157/V940 + pembrolizumab (KEYNOTE-942) | Safe and customizable; limited efficacy in poorly immunogenic tumors; slow onset of action |
| Bispecific antibodies (BiTEs, DARTs) | Redirect T cells to tumor cells using antibodies that bind both TCR (CD3) and TAAs | ALL, MM, DLBCL, SCLC, uveal melanoma | Blinatumomab (BiTE, FDA 2014; for B-ALL); Teclistamab (MM, FDA 2022); Epcoritamab (DLBCL, FDA 2023) | Efficient T cell redirection; short half-life; risk of CRS; complex dosing schedules |
| Adoptive cell therapies (ACTs) | Reinfuse TILs or engineered T cells (CAR-T, TCR-T) for direct cytotoxicity | B cell malignancies (approved), solid tumors (in trials) | Tisagenlecleucel (Kymriah, FDA 2017), Abecma (idecabtagene vicleucel, FDA 2021); TILs (lifileucel, FDA 2024; melanoma) | Highly specific and personalized; limited efficacy in solid tumors; manufacturing complexity; CRS and neurotoxicity risks |
| Cytokine therapies | Activate and expand immune effector cells using IL-2, IFN-α, IL-12, etc. | Metastatic melanoma, RCC; under evaluation for broader use | High-dose IL-2 (Proleukin, FDA 1992); Bempegaldesleukin (PEG-IL-2, trials in RCC—CheckMate-9ER) | Boosts immune activation; systemic toxicity and narrow therapeutic window; limited tumor targeting |
| Oncolytic viruses | Infect and lyse tumor cells while triggering innate/adaptive immune responses | Melanoma (T-VEC approved), trials in various solid tumors | T-VEC (Talimogene laherparepvec, FDA 2015 for melanoma); DNX-2401, Pexa-Vec (solid tumor trials) | Direct tumor lysis and immune activation; delivery challenges; antiviral immunity may limit efficacy |
| Synthetic immunomodulators | Stimulate innate sensors (e.g., STING, TLR9) and promote APC activation and T cell infiltration | Breast cancer models, potentially other solid tumors | STING agonists (ADU-S100, MK-1454 – NCT03937141); TLR9 agonist CMP-001 (melanoma trial NCT02680184) | Activate innate immunity; promising in combination therapies; limited monotherapy efficacy; potential off-target inflammation |
| Microbiome modulation | Modulate immune tone via gut flora using prebiotics, probiotics, FMT | Predictive of immunotherapy response and irAE risk; under clinical evaluation | Fecal microbiota transplant (FMT) in PD-1 refractory melanoma; SER-109 (CDI, FDA 2023) | Modulates systemic immunity; predictive for ICI response; interindividual variability and regulatory hurdles |
Emerging immunotherapeutic strategies in cancer treatment.
A key priority moving forward is the identification of robust biomarkers to guide patient stratification, predict therapeutic outcomes, and enable real-time monitoring of treatment responses. Clinically relevant biomarkers such as tumor mutational burden, microsatellite instability, immune cell infiltration, TGF-β signaling, prior treatment history, and proliferative capacity offer insights into treatment responsiveness (Usset et al., 2024). The integration of multi-omic data, including genomic, transcriptomic, proteomic, metabolomic, and microbiome-derived signatures, will be critical to the evolution of precision immunotherapy, facilitating the development of adaptive, context-specific therapeutic strategies while minimizing off-target toxicity (Sun et al., 2025).
As immunotherapy regimens become increasingly combinatorial, immune-related adverse events (irAEs) are emerging as a major clinical concern (). These toxicities, often affecting skin, liver, lung, gastrointestinal, and endocrine systems, can escalate with the intensity and complexity of treatment. Current management relies on early detection, corticosteroids, and biologic immunosuppressants (Schneider et al., 2021). However, future directions must include predictive biomarkers for irAE susceptibility, identification of molecular drivers, and implementation of prophylactic measures that do not compromise antitumor efficacy. Importantly, growing evidence links gut microbial composition to irAE development and therapeutic response, positioning microbiome modulation (probiotics, prebiotics, dietary changes, fecal microbiota transplantation) as a promising adjunctive approach ().
Innovations in nanotechnology, synthetic biology, and in vivo immune cell engineering are reshaping the immunotherapeutic landscape. Lipid nanoparticles, virus-mimetic vesicles, and programmable gene circuits enable precise targeting, context-sensitive activation, and scalable manufacturing of immune effectors. Concurrently, artificial intelligence and systems immunology are being leveraged to decode dynamic tumor–immune interactions, offering tools to personalize treatment regimens and predict long-term outcomes (; ). Chronotherapy, optimizing treatment timing based on circadian biology, is also emerging as a means to synchronize immunotherapeutic interventions with host immune rhythms, potentially improving efficacy and reducing toxicity (; Pérez-Villa et al., 2023).
Addressing disparities in access, response prediction, and trial inclusion remains essential to ensuring that immunotherapy benefits all patient populations. Current biomarker algorithms are often developed in predominantly Caucasian cohorts, limiting their applicability across ethnic groups. Expanding immunogenomic datasets, increasing representation in clinical trials, and studying racial and sex-based variability in immune responses will be vital to achieving global and equitable outcomes (; ; ).
Critical research priorities include determining whether early combination therapy can prevent resistance, optimizing sequencing and scheduling of agents to balance efficacy and safety, and further dissecting host–microbiota–immune interactions to enhance outcomes. In parallel, the development of bioresponsive materials, allogeneic cell therapies, and personalized neoantigen vaccines will likely redefine the scope of immunotherapy in coming years.
In conclusion, the future of cancer immunotherapy lies in a multifaceted, biomarker-guided framework that unites mechanistic understanding with clinical translation. By integrating next-generation immune targets, rational combinations, microbiome modulation, and advanced delivery systems, immunotherapy is poised to evolve from a breakthrough intervention into a cornerstone of curative oncology. Achieving this vision will require not only scientific innovation but also commitment to accessibility, inclusivity, and precision across every stage of cancer care.
Statements
Author contributions
NK: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. CE: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. JB: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. SR-O: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. MR-M: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. CS-S: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. JI-C: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. EO-P: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. SG: Data curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review and editing. AL-C: Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing, Conceptualization, Data curation, Formal Analysis.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by Universidad de Las Américas, Quito, Ecuador.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AbbasiS.TotmajM. A.AbbasiM.HajazimianS.GoleijP.BehrooziJ.et al (2023). Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer Med.12, 7844–7858. 10.1002/cam4.5551
2
AcharyaN.Sabatos-PeytonC.AndersonA. C. (2020). Tim-3 finds its place in the cancer immunotherapy landscape. J. Immunother. Cancer8, e000911. 10.1136/jitc-2020-000911
3
AlgaziA. P.TwittyC. G.TsaiK. K.LeM.PierceR.BrowningE.et al (2020). Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin. Cancer Res.26, 2827–2837. 10.1158/1078-0432.CCR-19-2217
4
AllenC.ZeidanA. M.BewersdorfJ. P. (2021). BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML?Life (Basel)11, 465. 10.3390/life11060465
5
AndtbackaR. H. I.KaufmanH. L.CollichioF.AmatrudaT.SenzerN.ChesneyJ.et al (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol.33, 2780–2788. 10.1200/JCO.2014.58.3377
6
Araujo-AbadS.BernaJ. M.Lloret-LopezE.López-CortésA.SacedaM.de Juan RomeroC. (2024). Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer. Cell Oncol. (Dordr)48, 269–293. 10.1007/s13402-024-00990-2
7
AsciertoP. A.StroyakovskiyD.GogasH.RobertC.LewisK.ProtsenkoS.et al (2023). Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol.24, 33–44. 10.1016/S1470-2045(22)00687-8
8
AsgharM. S.Ismail ShahS. M.RaniA.KazmiS.SavulI. S.UkraniJ.et al (2023). Toxicities of CAR T-cell therapy: a review of current literature. Ann. Med. Surg. (Lond)85, 6013–6020. 10.1097/MS9.0000000000001375
9
AungT.GrubbeW. S.NusbaumR. J.MendozaJ. L. (2023). Recent and future perspectives on engineering interferons and other cytokines as therapeutics. Trends biochem. Sci.48, 259–273. 10.1016/j.tibs.2022.09.005
10
AwadM. M.GovindanR.BaloghK. N.SpigelD. R.GaronE. B.BushwayM. E.et al (2022). Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell40, 1010–1026.e11. 10.1016/j.ccell.2022.08.003
11
BachanovaV.GhobadiA.PatelK.ParkJ. H.FlinnI. W.ShahP.et al (2021). Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma. Blood138, 823. 10.1182/blood-2021-151185
12
BautistaJ.Lopez-CortesA. (2025). Oncogenic viruses rewire the epigenome in human cancer. Front. Cell. Infect. Microbiol.15, 1617198. 10.3389/fcimb.2025.1617198
13
BautistaJ.Ojeda-MosqueraS.Ordóñez-LozadaD.López-CortésA. (2025). Peripheral clocks and systemic zeitgeber interactions: from molecular mechanisms to circadian precision medicine. Front. Endocrinol. (Lausanne)16, 1606242. 10.3389/fendo.2025.1606242
14
BerraondoP.SanmamedM. F.OchoaM. C.EtxeberriaI.AznarM. A.Pérez-GraciaJ. L.et al (2019). Cytokines in clinical cancer immunotherapy. Br. J. Cancer120, 6–15. 10.1038/s41416-018-0328-y
15
BlankC. U.LucasM. W.ScolyerR. A.van de WielB. A.MenziesA. M.Lopez-YurdaM.et al (2024). Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med.391, 1696–1708. 10.1056/NEJMoa2402604
16
BrandenburgA.HeineA.BrossartP. (2024). Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer10, 749–769. 10.1016/j.trecan.2024.06.003
17
BrissonM.KimJ. J.CanfellK.DroletM.GingrasG.BurgerE. A.et al (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet395, 575–590. 10.1016/S0140-6736(20)30068-4
18
ButterfieldL. H.NajjarY. G. (2024). Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat. Rev. Immunol.24, 399–416. 10.1038/s41577-023-00973-8
19
ChaeC.TakS. (2023). Estimated impact of the national hepatitis B immunization program on acute viral hepatitis B among adolescents in Republic of Korea. Osong Public Health Res. Perspect.14, 138–145. 10.24171/j.phrp.2022.0321
20
ChalabiM.VerschoorY. L.TanP. B.BalduzziS.Van LentA. U.GrootscholtenC.et al (2024). Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N. Engl. J. Med.390, 1949–1958. 10.1056/NEJMoa2400634
21
ChangJ. Y.VermaV.WelshJ. W.FormentiS. C. (2022). Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncol.23, e156. 10.1016/S1470-2045(22)00134-6
22
ChenS.LiJ.LiQ.WangZ. (2016). Bispecific antibodies in cancer immunotherapy. Hum. Vaccin. Immunother.12, 2491–2500. 10.1080/21645515.2016.1187802
23
ChenH.-L.WenW.-H.ChangM.-H. (2017). Management of pregnant women and children: focusing on preventing mother-to-infant transmission. J. Infect. Dis.216, S785–S791. 10.1093/infdis/jix429
24
ChenL.ZuoM.ZhouQ.WangY. (2023). Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front. Immunol.14, 1308890. 10.3389/fimmu.2023.1308890
25
ChiangC. L.-L.KandalaftL. E.TanyiJ.HagemannA. R.MotzG. T.SvoronosN.et al (2013). A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin. Cancer Res.19, 4801–4815. 10.1158/1078-0432.CCR-13-1185
26
ChoB. C.AbreuD. R.HusseinM.CoboM.PatelA. J.SecenN.et al (2022). Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol.23, 781–792. 10.1016/S1470-2045(22)00226-1
27
ChoueiriT. K.PowlesT.BurottoM.EscudierB.BourlonM. T.ZurawskiB.et al (2021a). Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.384, 829–841. 10.1056/NEJMoa2026982
28
ChoueiriT. K.TomczakP.ParkS. H.VenugopalB.FergusonT.ChangY.-H.et al (2021b). Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med.385, 683–694. 10.1056/NEJMoa2106391
29
ChuaA. V.DelmericoJ.ShengH.HuangX.-W.LiangE.YanL.et al (2025). Under-representation and under-reporting of minoritized racial and ethnic groups in clinical trials on immune checkpoint inhibitors. JCO Oncol. Pract.21, 408–417. 10.1200/OP.24.00033
30
CilloA. R.CardelloC.ShanF.KarapetyanL.KunningS.SanderC.et al (2024). Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell187, 4373–4388.e15. 10.1016/j.cell.2024.06.036
31
CoffinR. (2016). Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Immunotherapy8, 103–106. 10.2217/imt.15.116
32
CorrentiC. E.LaszloG. S.de van der SchuerenW. J.GodwinC. D.BandaranayakeA.BuschM. A.et al (2018). Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia32, 1239–1243. 10.1038/s41375-018-0014-3
33
CousinS.ToulmondeM.KindM.GueganJ.-P.BessedeA.CantarelC.et al (2022). Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. Exp. Hematol. Oncol.11, 104. 10.1186/s40164-022-00338-2
34
CurryW. T.GorrepatiR.PiescheM.SasadaT.AgarwallaP.JonesP. S.et al (2016). Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma. Clin. Cancer Res.22, 2885–2896. 10.1158/1078-0432.CCR-15-2163
35
DagherO. K.SchwabR. D.BrookensS. K.PoseyA. D. (2023). Advances in cancer immunotherapies. Cell186, 1814–1814.e1. 10.1016/j.cell.2023.02.039
36
DaiT.SunH.LibanT.Vicente-SuarezI.ZhangB.SongY.et al (2024). A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Sci. Rep.14, 10661. 10.1038/s41598-024-61477-6
37
DeegenP.ThomasO.Nolan-StevauxO.LiS.WahlJ.BognerP.et al (2021). The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer. Clin. Cancer Res.27, 2928–2937. 10.1158/1078-0432.CCR-20-3725
38
DhillonS. (2022). Tebentafusp: first approval. Drugs82, 703–710. 10.1007/s40265-022-01704-4
39
DhillonS. (2023). Elranatamab: first approval. Drugs83, 1621–1627. 10.1007/s40265-023-01954-w
40
DhillonS. (2024). Tarlatamab: first approval. Drugs84, 995–1003. 10.1007/s40265-024-02070-z
41
DokiY.AjaniJ. A.KatoK.XuJ.WyrwiczL.MotoyamaS.et al (2022). Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med.386, 449–462. 10.1056/NEJMoa2111380
42
DongH.LiM.YangC.WeiW.HeX.ChengG.et al (2023). Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. Cancer Cell Int.23, 1. 10.1186/s12935-022-02846-x
43
DroletM.BénardÉ.PérezN.BrissonM.HPV Vaccination Impact Study Group (2019). Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet394, 497–509. 10.1016/S0140-6736(19)30298-3
44
EcheverríaC. E.OyarzúnV. I.López-CortésA.CancinoJ.SotomayorP. C.GoncalvesM. D.et al (2024). Biological role of fructose in the male reproductive system: potential implications for prostate cancer. Prostate84, 8–24. 10.1002/pros.24631
45
FanT.ZhangM.YangJ.ZhuZ.CaoW.DongC. (2023). Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target. Ther.8, 450. 10.1038/s41392-023-01674-3
46
FelipE.AltorkiN.ZhouC.CsősziT.VynnychenkoI.GoloborodkoO.et al (2021). Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet398, 1344–1357. 10.1016/S0140-6736(21)02098-5
47
FinckA. V.BlanchardT.RoselleC. P.GolinelliG.JuneC. H. (2022). Engineered cellular immunotherapies in cancer and beyond. Nat. Med.28, 678–689. 10.1038/s41591-022-01765-8
48
FinnR. S.QinS.IkedaM.GalleP. R.DucreuxM.KimT.-Y.et al (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med.382, 1894–1905. 10.1056/NEJMoa1915745
49
FordeP. M.SpicerJ.LuS.ProvencioM.MitsudomiT.AwadM. M.et al (2022). Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med.386, 1973–1985. 10.1056/NEJMoa2202170
50
FramptonJ. E. (2023). Epcoritamab: first approval. Drugs83, 1331–1340. 10.1007/s40265-023-01930-4
51
FukuharaH.InoY.TodoT. (2016). Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci.107, 1373–1379. 10.1111/cas.13027
52
GalluzziL.HumeauJ.BuquéA.ZitvogelL.KroemerG. (2020). Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol.17, 725–741. 10.1038/s41571-020-0413-z
53
GalluzziL.AryankalayilM. J.ColemanC. N.FormentiS. C. (2023). Emerging evidence for adapting radiotherapy to immunotherapy. Nat. Rev. Clin. Oncol.20, 543–557. 10.1038/s41571-023-00782-x
54
García-CárdenasJ. M.IndacocheaA.Pesantez-CoronelD.Terán-NavasM.AleagaA.Armendáriz-CastilloI.et al (2024). Toward equitable precision oncology: monitoring racial and ethnic inclusion in genomics and clinical trials. JCO Precis. Oncol.8, e2300398. 10.1200/PO.23.00398
55
GeoergerB.GrillJ.OpolonP.MorizetJ.AubertG.Terrier-LacombeM.-J.et al (2002). Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res.62, 764–772.
56
GevaR.VoskoboynikM.DobrenkovK.MayawalaK.GwoJ.WnekR.et al (2020). First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer126, 4926–4935. 10.1002/cncr.33133
57
GhobadiA.BachanovaV.PatelK.ParkJ. H.FlinnI.RiedellP. A.et al (2025). Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet405, 127–136. 10.1016/S0140-6736(24)02462-0
58
GoebelerM.-E.BargouR. (2016). Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk. Lymphoma57, 1021–1032. 10.3109/10428194.2016.1161185
59
GöpfrichK.PlattenM.FrischknechtF.FacklerO. T. (2024). Bottom-up synthetic immunology. Nat. Nanotechnol.19, 1587–1596. 10.1038/s41565-024-01744-9
60
GoswamiS.PaukenK. E.WangL.SharmaP. (2024). Next-generation combination approaches for immune checkpoint therapy. Nat. Immunol.25, 2186–2199. 10.1038/s41590-024-02015-4
61
Goyco VeraD.WaghelaH.NuhM.PanJ.LullaP. (2024). Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum. Vaccin. Immunother.20, 2378543. 10.1080/21645515.2024.2378543
62
GrosserR.CherkasskyL.ChintalaN.AdusumilliP. S. (2019). Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell36, 471–482. 10.1016/j.ccell.2019.09.006
63
GuerreroS.López-CortésA.IndacocheaA.García-CárdenasJ. M.ZambranoA. K.Cabrera-AndradeA.et al (2018). Analysis of racial/ethnic representation in select basic and applied cancer research studies. Sci. Rep.8, 13978. 10.1038/s41598-018-32264-x
64
GuoY.Quijano CardéN. A.KangL.VeronaR.BanerjeeA.KobosR.et al (2024). Teclistamab: mechanism of action, clinical, and translational science. Clin. Transl. Sci.17, e13717. 10.1111/cts.13717
65
HaflerD. A. (2007). Cytokines and interventional immunology. Nat. Rev. Immunol.7, 423. 10.1038/nri2101
66
HamoudaA. E. I.FiltjensJ.BrabantsE.KanchevaD.DebraekeleerA.BrughmansJ.et al (2024). Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat. Commun.15, 10635. 10.1038/s41467-024-54877-9
67
HanselT. T.KropshoferH.SingerT.MitchellJ. A.GeorgeA. J. T. (2010). The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov.9, 325–338. 10.1038/nrd3003
68
HeidbuechelJ. P. W.EngelandC. E. (2021). Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J. Hematol. Oncol.14, 63. 10.1186/s13045-021-01075-5
69
HellmannM. D.BiviN.CalderonB.ShimizuT.DelafontaineB.LiuZ. T.et al (2021). Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors. Clin. Cancer Res.27, 2773–2781. 10.1158/1078-0432.CCR-20-3716
70
HerreraM.PretelliG.DesaiJ.GarraldaE.SiuL. L.SteinerT. M.et al (2024). Bispecific antibodies: advancing precision oncology. Trends Cancer10, 893–919. 10.1016/j.trecan.2024.07.002
71
HongM.ClubbJ. D.ChenY. Y. (2020). Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell38, 473–488. 10.1016/j.ccell.2020.07.005
72
HornL.MansfieldA. S.SzczęsnaA.HavelL.KrzakowskiM.HochmairM. J.et al (2018). First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med.379, 2220–2229. 10.1056/NEJMoa1809064
73
HsuC.-H.LuZ.GaoS.WangJ.-Y.SunJ.-M.LiuT.et al (2024). SKYSCRAPER-08: a phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). JCO42, 245. 10.1200/JCO.2024.42.3_suppl.245
74
HuduS. A.OsmanA.Abu-ShouraE. J. I.JimohA. O. (2024). A critical review of the prospects and challenges of Hepatitis B therapeutic vaccines. Trends Immunother.8, 5644. 10.24294/ti.v8.i1.5644
75
HunterT. L.BaoY.ZhangY.MatsudaD.RienerR.WangA.et al (2025). In vivo CAR T cell generation to treat cancer and autoimmune disease. Science388, 1311–1317. 10.1126/science.ads8473
76
HuoberJ.BarriosC. H.NiikuraN.JarząbM.ChangY.-C.Huggins-PuhallaS. L.et al (2022). Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial. J. Clin. Oncol.40, 2946–2956. 10.1200/JCO.21.02772
77
HutchingsM.MorschhauserF.IacoboniG.Carlo-StellaC.OffnerF. C.SuredaA.et al (2021). Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol.39, 1959–1970. 10.1200/JCO.20.03175
78
JuneC. H.O’ConnorR. S.KawalekarO. U.GhassemiS.MiloneM. C. (2018). CAR T cell immunotherapy for human cancer. Science359, 1361–1365. 10.1126/science.aar6711
79
KamatN. V.YuE. Y.LeeJ. K. (2021). BiTE-ing into prostate cancer with bispecific T-cell engagers. Clin. Cancer Res.27, 2675–2677. 10.1158/1078-0432.CCR-21-0355
80
KangX.LauH. C.-H.YuJ. (2024). Modulating gut microbiome in cancer immunotherapy: harnessing microbes to enhance treatment efficacy. Cell Rep. Med.5, 101478. 10.1016/j.xcrm.2024.101478
81
KantoffP. W.HiganoC. S.ShoreN. D.BergerE. R.SmallE. J.PensonD. F.et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363, 411–422. 10.1056/NEJMoa1001294
82
KapetanovicE.WeberC. R.BruandM.PöschlD.KucharczykJ.HirthE.et al (2024). Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies. Nat. Biomed. Eng.8, 1665–1681. 10.1038/s41551-024-01255-x
83
KaufmanH. L.KohlhappF. J.ZlozaA. (2015). Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov.14, 642–662. 10.1038/nrd4663
84
KeamS. J. (2023). Talquetamab: first approval. Drugs83, 1439–1445. 10.1007/s40265-023-01945-x
85
KimS.WuthrickE.BlakajD.ErogluZ.VerschraegenC.ThapaR.et al (2022). Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet400, 1008–1019. 10.1016/S0140-6736(22)01659-2
86
KimE. H.TeerdhalaS. V.PadillaM. S.JosephR. A.LiJ. J.HaleyR. M.et al (2024). Lipid nanoparticle-mediated RNA delivery for immune cell modulation. Eur. J. Immunol.54, e2451008. 10.1002/eji.202451008
87
KleinC.BrinkmannU.ReichertJ. M.KontermannR. E. (2024). The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov.23, 301–319. 10.1038/s41573-024-00896-6
88
KlichinskyM.RuellaM.ShestovaO.LuX. M.BestA.ZeemanM.et al (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol.38, 947–953. 10.1038/s41587-020-0462-y
89
KonetyB. R.ShoreN. D.SantG. R. (2024). Clinical use of nadofaragene firadenovec-vncg. Ther. Adv. Urol.16, 17562872241280005. 10.1177/17562872241280005
90
KovácsS. A.FeketeJ. T.GyőrffyB. (2023). Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. Acta Pharmacol. Sin.44, 1879–1889. 10.1038/s41401-023-01079-6
91
KrishnamoorthyM.LenehanJ. G.Maleki VarekiS. (2021). Neoadjuvant immunotherapy for high-risk, resectable malignancies: scientific rationale and clinical challenges. J. Natl. Cancer Inst.113, 823–832. 10.1093/jnci/djaa216
92
KryskoD. V.GargA. D.KaczmarekA.KryskoO.AgostinisP.VandenabeeleP. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer12, 860–875. 10.1038/nrc3380
93
KühlL.AschmoneitN.KontermannR. E.SeifertO. (2022). The eIg technology to generate Ig-like bispecific antibodies. MAbs14, 2063043. 10.1080/19420862.2022.2063043
94
KyriakidisN. C.López-CortésA.GonzálezE. V.GrimaldosA. B.PradoE. O. (2021). SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines6, 28. 10.1038/s41541-021-00292-w
95
LaRoccaC. J.WarnerS. G. (2018). Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin. Transl. Med.7, 35. 10.1186/s40169-018-0214-5
96
LeeN.JeonY.-H.YooJ.ShinS.-K.LeeS.ParkM.-J.et al (2023). Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies. J. Immunother. Cancer11, e006024. 10.1136/jitc-2022-006024
97
LeeD.HuntoonK.WangY.KangM.LuY.JeongS. D.et al (2024). Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nat. Biomed. Eng.8, 593–610. 10.1038/s41551-024-01194-7
98
LiY.-R.ZhuY.HalladayT.YangL. (2025). In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol.10.1038/s41577-025-01174-1
99
LinX.SunY.DongX.LiuZ.SugimuraR.XieG. (2023). IPSC-derived CAR-NK cells for cancer immunotherapy. Biomed. Pharmacother.165, 115123. 10.1016/j.biopha.2023.115123
100
LivingstoneE.ZimmerL.HasselJ. C.FluckM.EigentlerT. K.LoquaiC.et al (2022). Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet400, 1117–1129. 10.1016/S0140-6736(22)01654-3
101
LongG. V.ShklovskayaE.SatgunaseelanL.MaoY.da SilvaI. P.PerryK. A.et al (2025). Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat. Med.31, 1557–1566. 10.1038/s41591-025-03512-1
102
LuY.YuanX.WangM.HeZ.LiH.WangJ.et al (2022). Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J. Hematol. Oncol.15, 47. 10.1186/s13045-022-01273-9
103
LuiG.MinnarC. M.Soon-ShiongP.SchlomJ.GameiroS. R. (2023). Exploiting an interleukin-15 heterodimeric agonist (N803) for effective immunotherapy of solid malignancies. Cells12, 1611. 10.3390/cells12121611
104
MaR.LiZ.ChioccaE. A.CaligiuriM. A.YuJ. (2023). The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer9, 122–139. 10.1016/j.trecan.2022.10.003
105
MakkerV.ColomboN.Casado HerráezA.SantinA. D.ColombaE.MillerD. S.et al (2022). Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med.386, 437–448. 10.1056/NEJMoa2108330
106
MartinsF.SofiyaL.SykiotisG. P.LamineF.MaillardM.FragaM.et al (2019). Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol.16, 563–580. 10.1038/s41571-019-0218-0
107
MitraA.BaruaA.HuangL.GangulyS.FengQ.HeB. (2023). From bench to bedside: the history and progress of CAR T cell therapy. Front. Immunol.14, 1188049. 10.3389/fimmu.2023.1188049
108
MoradG.HelminkB. A.SharmaP.WargoJ. A. (2021). Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell184, 5309–5337. 10.1016/j.cell.2021.09.020
109
MorottiM.AlbukhariA.AlsaadiA.ArtibaniM.BrentonJ. D.CurbishleyS. M.et al (2021). Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer124, 1759–1776. 10.1038/s41416-021-01353-6
110
MorvaA.ArroyoA. B.AndreevaL.Tapia-AbellánA.Luengo-GilG. (2025). Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review. Front. Immunol.16, 1615760. 10.3389/fimmu.2025.1615760
111
NagasakiJ.IshinoT.TogashiY. (2022). Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci.113, 3303–3312. 10.1111/cas.15497
112
NarayanV. M.BoorjianS. A.AlemozaffarM.KonetyB. R.ShoreN. D.GomellaL. G.et al (2024). Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus calmette-guérin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial. J. Urol.212, 74–86. 10.1097/JU.0000000000004020
113
NormanK. L.LeeP. W. (2000). Reovirus as a novel oncolytic agent. J. Clin. Invest.105, 1035–1038. 10.1172/JCI9871
114
OlsonD. J.ErogluZ.BrocksteinB.PoklepovicA. S.BajajM.BabuS.et al (2021). Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J. Clin. Oncol.39, 2647–2655. 10.1200/JCO.21.00079
115
OttP. A.HuZ.KeskinD. B.ShuklaS. A.SunJ.BozymD. J.et al (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature547, 217–221. 10.1038/nature22991
116
OttP. A.Hu-LieskovanS.ChmielowskiB.GovindanR.NaingA.BhardwajN.et al (2020). A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell183, 347–362.e24. e24. 10.1016/j.cell.2020.08.053
117
PakkalaS.HigginsK.ChenZ.SicaG.SteuerC.ZhangC.et al (2020). Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. J. Immunother. Cancer8, e001302. 10.1136/jitc-2020-001302
118
PaleckiJ.BhasinA.BernsteinA.MilleP. J.TesterW. J.KellyW. K.et al (2024). T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. Cancer Biol. Ther.25, 2356820. 10.1080/15384047.2024.2356820
119
PardollD. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12, 252–264. 10.1038/nrc3239
120
PengL.SferruzzaG.YangL.ZhouL.ChenS. (2024). CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell. Mol. Immunol.21, 1089–1108. 10.1038/s41423-024-01207-0
121
Pérez-VillaA.Echeverría-GarcésG.Ramos-MedinaM. J.PrathapL.Martínez-LópezM.Ramírez-SánchezD.et al (2023). Integrated multi-omics analysis reveals the molecular interplay between circadian clocks and cancer pathogenesis. Sci. Rep.13, 14198. 10.1038/s41598-023-39401-1
122
Postel-VinayS.LamV. K.RosW.BauerT. M.HansenA. R.ChoD. C.et al (2023). First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J. Immunother. Cancer11, e005301. 10.1136/jitc-2022-005301
123
ReddyR.YanS. C.Hasanpour SegherlouZ.Hosseini-SiyanakiM.-R.PoeJ.Perez-VegaC.et al (2024). Oncolytic viral therapy: a review and promising future directions. J. Neurosurg.140, 319–327. 10.3171/2023.6.JNS23243
124
ReissK. A.YuanY.UenoN. T.JohnsonM. L.GillS.DeesE. C.et al (2022). A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. JCO40, 2533. 10.1200/JCO.2022.40.16_suppl.2533
125
ReissK. A.AngelosM. G.DeesE. C.YuanY.UenoN. T.PohlmannP. R.et al (2025). CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med.31, 1171–1182. 10.1038/s41591-025-03495-z
126
RezvaniK. (2019). Adoptive cell therapy using engineered natural killer cells. Bone Marrow Transpl.54, 785–788. 10.1038/s41409-019-0601-6
127
RibasA.WolchokJ. D. (2018). Cancer immunotherapy using checkpoint blockade. Science359, 1350–1355. 10.1126/science.aar4060
128
RiniB. I.PlimackE. R.StusV.GafanovR.HawkinsR.NosovD.et al (2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380, 1116–1127. 10.1056/NEJMoa1816714
129
Rivera-OrellanaS.BautistaJ.Palacios-ZavalaD.Ojeda-MosqueraS.Altamirano-ColinaA.Alcocer-VeintimillaM.et al (2025). Oncolytic virotherapy and tumor microenvironment modulation. Clin. Exp. Med.25, 256. 10.1007/s10238-025-01691-2
130
RomeeR.CooleyS.Berrien-ElliottM. M.WesterveltP.VernerisM. R.WagnerJ. E.et al (2018). First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood131, 2515–2527. 10.1182/blood-2017-12-823757
131
RousseauA.ParisiC.BarlesiF. (2023). Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open8, 101184. 10.1016/j.esmoop.2023.101184
132
Safarzadeh KozaniP.NaseriA.MirarefinS. M. J.SalemF.NikbakhtM.Evazi BakhshiS.et al (2022). Nanobody-based CAR-T cells for cancer immunotherapy. Biomark. Res.10, 24. 10.1186/s40364-022-00371-7
133
SantomassoB. D.GustJ.PernaF. (2023). How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood141, 2443–2451. 10.1182/blood.2022017604
134
SauerN.JanickaN.SzlasaW.SkinderowiczB.KołodzińskaK.DwernickaW.et al (2023). TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol. Immunother.72, 3405–3425. 10.1007/s00262-023-03516-1
135
SaxenaM.van der BurgS. H.MeliefC. J. M.BhardwajN. (2021). Therapeutic cancer vaccines. Nat. Rev. Cancer21, 360–378. 10.1038/s41568-021-00346-0
136
SaxtonR. A.GlassmanC. R.GarciaK. C. (2023). Emerging principles of cytokine pharmacology and therapeutics. Nat. Rev. Drug Discov.22, 21–37. 10.1038/s41573-022-00557-6
137
SchneiderB. J.NaidooJ.SantomassoB. D.LacchettiC.AdkinsS.AnadkatM.et al (2021). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol.39, 4073–4126. 10.1200/JCO.21.01440
138
SchoenfeldA. J.HellmannM. D. (2020). Acquired resistance to immune checkpoint inhibitors. Cancer Cell37, 443–455. 10.1016/j.ccell.2020.03.017
139
SchoenfeldJ. D.Giobbie-HurderA.RanasingheS.KaoK. Z.LakoA.TsujiJ.et al (2022). Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol.23, 279–291. 10.1016/S1470-2045(21)00658-6
140
SehnL. H.BartlettN. L.MatasarM. J.SchusterS. J.AssoulineS. E.GiriP.et al (2025). Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood145, 708–719. 10.1182/blood.2024025454
141
SethnaZ.GuaspP.ReicheC.MilighettiM.CegliaN.PattersonE.et al (2025). RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature639, 1042–1051. 10.1038/s41586-024-08508-4
142
ShalhoutS. Z.MillerD. M.EmerickK. S.KaufmanH. L. (2023). Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol.20, 160–177. 10.1038/s41571-022-00719-w
143
SharmaP.GoswamiS.RaychaudhuriD.SiddiquiB. A.SinghP.NagarajanA.et al (2023). Immune checkpoint therapy-current perspectives and future directions. Cell186, 1652–1669. 10.1016/j.cell.2023.03.006
144
SilvaD.-A.YuS.UlgeU. Y.SpanglerJ. B.JudeK. M.Labão-AlmeidaC.et al (2019). De novo design of potent and selective mimics of IL-2 and IL-15. Nature565, 186–191. 10.1038/s41586-018-0830-7
145
SimãoD. C.ZarrabiK. K.MendesJ. L.LuzR.GarciaJ. A.KellyW. K.et al (2023). Bispecific T-cell engagers therapies in solid tumors: focusing on prostate cancer. Cancers (Basel)15, 1412. 10.3390/cancers15051412
146
SplawnL. M.BaileyC. A.MedinaJ. P.ChoJ. C. (2018). Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States. Drugs Today54, 399–405. 10.1358/dot.2018.54.7.2833984
147
SunL. L.EllermanD.MathieuM.HristopoulosM.ChenX.LiY.et al (2015). Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci. Transl. Med.7, 287ra70. 10.1126/scitranslmed.aaa4802
148
SunQ.HongZ.ZhangC.WangL.HanZ.MaD. (2023). Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct. Target. Ther.8, 320. 10.1038/s41392-023-01522-4
149
SunJ.SongS.LiuJ.ChenF.LiX.WuG. (2025). Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation. npj Biofilms Microbiomes11, 43. 10.1038/s41522-025-00678-x
150
SvensonJ.MolchanovaN.SchroederC. I. (2022). Antimicrobial peptide mimics for clinical use: does size matter?Front. Immunol.13, 915368. 10.3389/fimmu.2022.915368
151
SzijjP. A.GrayM. A.RibiM. K.BahouC.NogueiraJ. C. F.BertozziC. R.et al (2023). Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer. Nat. Chem.15, 1636–1647. 10.1038/s41557-023-01280-4
152
TawbiH. A.SchadendorfD.LipsonE. J.AsciertoP. A.MatamalaL.Castillo GutiérrezE.et al (2022). Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med.386, 24–34. 10.1056/NEJMoa2109970
153
TianZ.LiuM.ZhangY.WangX. (2021). Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J. Hematol. Oncol.14, 75. 10.1186/s13045-021-01084-4
154
TrabolsiA.ArumovA.SchatzJ. H. (2024). Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J.14, 27. 10.1038/s41408-024-00997-w
155
Twyman-Saint VictorC.RechA. J.MaityA.RenganR.PaukenK. E.StelekatiE.et al (2015). Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature520, 373–377. 10.1038/nature14292
156
UssetJ.Rosendahl HuberA.AndrianovaM. A.BatlleE.CarlesJ.CuppenE.et al (2024). Five latent factors underlie response to immunotherapy. Nat. Genet.56, 2112–2120. 10.1038/s41588-024-01899-0
157
van der HeijdenM. S.SonpavdeG.PowlesT.NecchiA.BurottoM.SchenkerM.et al (2023). Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N. Engl. J. Med.389, 1778–1789. 10.1056/NEJMoa2309863
158
VormehrM.TüreciÖ.SahinU. (2019). Harnessing tumor mutations for truly individualized cancer vaccines. Annu. Rev. Med.70, 395–407. 10.1146/annurev-med-042617-101816
159
WakeleeH.LibermanM.KatoT.TsuboiM.LeeS.-H.GaoS.et al (2023). Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N. Engl. J. Med.389, 491–503. 10.1056/NEJMoa2302983
160
WangD.-R.WuX.-L.SunY.-L. (2022). Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct. Target. Ther.7, 331. 10.1038/s41392-022-01136-2
161
WangR.KubiatowiczL. J.ZhangR.BaoL.FangR. H.ZhangL. (2025). Nanoparticle approaches for manipulating cytokine delivery and neutralization. Front. Immunol.16, 1592795. 10.3389/fimmu.2025.1592795
162
WeissA. M.HossainyS.RowanS. J.HubbellJ. A.Esser-KahnA. P. (2022). Immunostimulatory polymers as adjuvants, immunotherapies, and delivery systems. Macromolecules55, 6913–6937. 10.1021/acs.macromol.2c00854
163
WolchokJ. D.Chiarion-SileniV.GonzalezR.GrobJ.-J.RutkowskiP.LaoC. D.et al (2022). Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol.40, 127–137. 10.1200/JCO.21.02229
164
YinY.RodriguezJ. L.LiN.ThokalaR.NasrallahM. P.HuL.et al (2022). Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol. Ther.30, 2537–2553. 10.1016/j.ymthe.2022.05.011
165
ZaidiN.JaffeeE. M.YarchoanM. (2025). Recent advances in therapeutic cancer vaccines. Nat. Rev. Cancer.25, 517–533. 10.1038/s41568-025-00820-z
166
ZhangS.RabkinS. D. (2021). The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?Expert Opin. Drug Discov.16, 391–410. 10.1080/17460441.2021.1850689
167
ZhangZ.LiuX.ChenD.YuJ. (2022). Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct. Target. Ther.7, 258. 10.1038/s41392-022-01102-y
168
ZhangY.-Y.HeJ.-J.LiuY.-L.ShaoR.-N.BaiK.-H.LiX.-P.et al (2025). Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy. NPJ Precis. Oncol.9, 142. 10.1038/s41698-025-00933-6
169
ZhaoZ.CondominesM.van der StegenS. J. C.PernaF.KlossC. C.GunsetG.et al (2015). Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell28, 415–428. 10.1016/j.ccell.2015.09.004
170
ZhengD.LiwinskiT.ElinavE. (2020). Interaction between microbiota and immunity in health and disease. Cell Res.30, 492–506. 10.1038/s41422-020-0332-7
171
ZhengY.XuR.ChenX.LuY.ZhengJ.LinY.et al (2024). Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. Cell Death Dis.15, 775. 10.1038/s41419-024-07122-6
172
ZhengB.WangX.GuoM.TzengC.-M. (2025). Therapeutic peptides: recent advances in discovery, synthesis, and clinical translation. ijms26, 5131. 10.3390/ijms26115131
173
ZibelmanM.MacFarlaneA. W.CostelloK.McGowanT.O’NeillJ.KokateR.et al (2023). A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. Nat. Commun.14, 4513. 10.1038/s41467-023-40028-z
174
ZugastiI.Espinosa-ArocaL.FidytK.Mulens-AriasV.Diaz-BeyaM.JuanM.et al (2025). CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct. Target. Ther.10, 210. 10.1038/s41392-025-02269-w
Summary
Keywords
cancer immunotherapy, immune checkpoints, adoptive cell therapy, next-generation therapeutics, biomarker-guided precision medicine, tumor microenvironment
Citation
Kyriakidis NC, Echeverría CE, Bautista J, Rivera-Orellana S, Ramos-Medina MJ, Salazar-Santoliva C, Izquierdo-Condoy JS, Ortiz-Prado E, Guerrero S and López-Cortés A (2025) Reprogramming cancer immunity with next-generation combination therapies. Front. Cell Dev. Biol. 13:1652047. doi: 10.3389/fcell.2025.1652047
Received
23 June 2025
Accepted
11 August 2025
Published
28 August 2025
Volume
13 - 2025
Edited by
Brunie H. Felding, The Scripps Research Institute, United States
Reviewed by
Yujie Shi, The Scripps Research Institute, United States
Feng Lin, Curescience Institute, United States
Updates
Copyright
© 2025 Kyriakidis, Echeverría, Bautista, Rivera-Orellana, Ramos-Medina, Salazar-Santoliva, Izquierdo-Condoy, Ortiz-Prado, Guerrero and López-Cortés.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Andrés López-Cortés, aalc84@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.